RecruitingNot ApplicableNCT04073797

PET Imaging of Inflammation and Lipid Lowering Study

Sponsor

University of Cambridge

Enrollment

63 participants

Start Date

Mar 20, 2023

Study Type

INTERVENTIONAL

Conditions

Atherosclerosis Hypercholesterolemia Carotid Artery Plaque Hypercholesterolemia, Familial

Summary

While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging has been used as an early marker of drug efficacy in numerous clinical cardiovascular drug trials, as a glucose analog, its signal in the vasculature lacks inflammatory cell-specificity. Moreover, high background 18F-FDG signals from the myocardium often preclude coronary artery imaging, despite attempts to suppress myocardial tracer uptake by dietary manipulation. These limitations of 18F-FDG for measuring changes in vascular inflammation arising from drug intervention highlight important unmet needs, which might be overcome by using a somatostatin receptor subtype-2 (SST2) PET tracer.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying 68Ga-DOTATATE PET-MRI, a drug called Colchicine, and others for people with atherosclerosis, carotid artery plaque, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.